摘要 |
The present invention relates to extended release formulations comprising dipraglurant, a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator, or a pharmaceutically acceptable salt thereof, for oral administration. The invention further provides a process for preparing these extended releases formulations and their use in the prevention or treatment disorders related to mGluR5 negative allosteric modulators. |